타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Imdelltra (tarlatamab) |
Overview Company | Amgen |
Overview Modality | ANTIBODY |
Overview Target | DLL3 × CD3 |
Overview Indication | Extensive-stage small cell lung cancer after platinum-based chemotherapy |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | DLL3 is expressed on ~85–95% of SCLC tumors but almost absent from normal tissue, which is rare for a solid-tumor engager target. |
Positioning Known limitation | Neuroendocrine-to-non-neuroendocrine plasticity with DLL3 loss; T-cell exhaustion. |
Positioning Development positioning | 2L+ |
MoA Mechanism | Binds DLL3 on SCLC cells and CD3 on T cells, forcing a cytolytic synapse that kills tumor cells regardless of native TCR specificity. |
MoA Biomarker | DLL3 expression by IHC is not required in the label but tracks with the biology. |
Toxicology Major finding | Boxed warning for CRS and neurologic toxicity including ICANS. Cytopenia and fatigue are common; step-up dosing with monitoring is mandatory. |
Toxicology CRS | CRS ~51–55%, mostly grade 1–2 |
Clinical Safety signal | Boxed warning for CRS and neurologic toxicity including ICANS. Cytopenia and fatigue are common; step-up dosing with monitoring is mandatory. |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Imdelltra (tarlatamab) |
Overview Company | Amgen |
Overview Modality | ANTIBODY |
Overview Target | DLL3 × CD3 |
Overview Indication | Extensive-stage small cell lung cancer after platinum-based chemotherapy |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | DLL3 is expressed on ~85–95% of SCLC tumors but almost absent from normal tissue, which is rare for a solid-tumor engager target. |
Positioning Known limitation | Neuroendocrine-to-non-neuroendocrine plasticity with DLL3 loss; T-cell exhaustion. |
Positioning Development positioning | 2L+ |
MoA Mechanism | Binds DLL3 on SCLC cells and CD3 on T cells, forcing a cytolytic synapse that kills tumor cells regardless of native TCR specificity. |
MoA Biomarker | DLL3 expression by IHC is not required in the label but tracks with the biology. |
Toxicology Major finding | Boxed warning for CRS and neurologic toxicity including ICANS. Cytopenia and fatigue are common; step-up dosing with monitoring is mandatory. |
Toxicology CRS | CRS ~51–55%, mostly grade 1–2 |
Clinical Safety signal | Boxed warning for CRS and neurologic toxicity including ICANS. Cytopenia and fatigue are common; step-up dosing with monitoring is mandatory. |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
추천 비교
추천 비교